SEC Tracker
Get the app

bioAffinity Technologies BIAF

bioAffinity Technologies announces data presentation

Form
8-K
Filed
Importance
Routine
  1. Presenting data at CHEST 2026 on sputum-based tests for lung inflammation.
  2. Tests detect protein biomarkers including biologic drug targets for asthma and COPD.
  3. Research aims to support precision medicine approach for lung disease treatment.
  4. Global asthma therapeutics market projected to reach $47.6 billion by 2034.

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when bioAffinity Technologies files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 8731 and related industry codes: the same peer list as the financial tables.

  1. IB Acquisition IBAC public float $15M, Mar 31, 2025, over 18 months old
  2. OneMedNet ONMD public float $14M, Jun 30, 2025
  3. 20/20 Biolabs AIDX
  4. Inotiv NOTV public float $71M, Mar 31, 2025, over 18 months old